SCHEMBL4629225

SCHEMBL4629225

NC(=Nc1ccc(OCc2ccccc2)cc1)NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN2A Q99250 4/20 0.80
▸ PARP10 Q53GL7 1/20 0.53
▸ NPC1 O15118 4/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ SCN5A Q14524 3/20 0.53
▸ NR4A2 P43354 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ POLB P06746 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ SENP8 Q96LD8 1/20 0.50
▸ SENP7 Q9BQF6 1/20 0.50
▸ SENP6 Q9GZR1 1/20 0.50
▸ ALOX12 P18054 1/20 0.50
▸ BCL2L1 Q07817 1/20 0.49
▸ MCL1 Q07820 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628694 0.92 SCN2A (0.84) SCN2APARP10NPC1RAB9ASCN5A
SCHEMBL4628674 0.89 SCN2A (0.83) SCN2APARP10NPC1RAB9ASCN5A
SCHEMBL4628980 0.89 SCN2A (1.00) SCN2APARP10SCN5AALDH1A1MAPT
SCHEMBL4628715 0.88 SCN2A (0.72) SCN2APARP10NPC1RAB9ASCN5A
SCHEMBL4627487 0.85 SCN2A (0.61) SCN2ANPC1RAB9ASCN5AALDH1A1
SCHEMBL4627497 0.84 SCN2A (0.66) SCN2APARP10NPC1RAB9ASCN5A
SCHEMBL4628807 0.84 SCN2A (0.66) SCN2APARP10NPC1RAB9ASCN5A
SCHEMBL4628983 0.81 SCN2A (0.62) SCN2APARP10NPC1RAB9ASCN5A
SCHEMBL4627476 0.81 SCN2A (0.69) SCN2APARP10NPC1RAB9ASMN1; SMN2
SCHEMBL4628743 0.81 SCN2A (0.67) SCN2APARP10NPC1RAB9ANR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 — — EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 — — US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 — — EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 — — EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 — — US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN2A 1613/4885PARP10 1248/4885NPC1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback